Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Burkitt Lymphoma 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 3Leukemia, Myeloid, Acute 2Leukemia, Biphenotypic, Acute 2Renal Pelvis and Ureter Urothelial Carcinoma 1Primary Myelofibrosis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Osteosarcoma 1Oropharyngeal Neoplasms 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Mouth Neoplasms 1Leukemia, Myelomonocytic, Juvenile 1Leukemia, Myeloid, Accelerated Phase 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Hematopoietic and Lymphatic System Neoplasm 1Head and Neck Neoplasms 1Down Syndrome 1Carcinoma 1Blastic Plasmacytoid Dendritic Cell Neoplasm 1Blast Crisis 1

Interventions

Cytarabine 2pegaspargase 1merphos 1hydrocortisone hemisuccinate 1dexamethasone acetate 1dexamethasone 21-phosphate 1calaspargase pegol 1blinatumomab 1azathiopurine 1auricularum 1Vincristine 1Spinal Puncture 1Specimen Handling 1Radiotherapy, Conformal 1Nivolumab 1N,N-dicyclohexyl-isoborneol-10-sulfonamide 1Methotrexate 1Mercaptopurine 1Idarubicin 1Hydrocortisone 1Etoposide 1Dexamethasone 1Daunorubicin 1Calcium Dobesilate 1Biopsy 1Asparaginase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Down Syndrome × merphos × Clear all
NCT04546399 2025-09-10

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

National Cancer Institute (NCI)

Phase 2 Recruiting
461 enrolled
Lymphoid

Burkitt Lymphoma, Down Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡